Clinical trials: Breast Cancer Stage IV
Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic)
Immune Cell Therapy for Advanced Solid Tumors
The autologous immune cell induction technology used in this project involves transforming peripheral blood mononuclear cells (PBMC) into autologous DC cells, NK cells, CIK cells and other immune cells through cytokine induction…
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic), Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07260058
- Testing
- Autologous immune Cells, Standard chemotherapy
- Volunteers
- 48 people
- Sponsor
- Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Breast Cancer
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial in China will evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel compared with placebo + trastuzumab + docetaxel in…
- Trial name
- PUFFIN (NCT02896855)
- Testing
- Docetaxel, Pertuzumab, Trastuzumab
- Where
- 15 sites in China
- Volunteers
- 243 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Breast
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
This study was designed to be two-part study (Phase I/Phase II). Part I was designed to find the optimal (best) doses of GW572016, docetaxel, and trastuzumab when given together.
- Trial name
- NCT00251433
- Testing
- lapatinib, docetaxel, trastuzumab
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Unresectable or Metastatic Breast Cancer of Adults
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209…
- Trial name
- NCT07389733
- Testing
- HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Breast Neoplasm
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
In this study the investigators assess the impact of the eHealth-supported therapy management system CANKADO on Quality of Life in patients with HR+, HER2-locally advanced or metastatic breast cancer treated with the cyclin…
- Trial name
- PRECYCLE (NCT03220178)
- Testing
- Palbociclib, Fulvestrant, Anastrozole
- Where
- Germany
- Volunteers
- 532 people
- Sponsor
- Palleos Healthcare GmbH
Locally Advanced Breast Cancer, Metastatic Breast Cancer
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
- Trial name
- EFECT (NCT00065325)
- Testing
- Fulvestrant, Exemestane
- Where
- 117 sites in United States, Argentina and 13 more
- Volunteers
- 694 people
- Sponsor
- AstraZeneca
Breast Cancer, Metastatic Breast Cancer
Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer
This study was designed to evaluate safety and tolerability of Herceptin as treatment for patients with human epidermal growth factor receptor 2 (HER-2) positive metastatic breast cancer.
- Trial name
- NCT02424682
- Testing
- No intervention
- Where
- Serbia
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
This single arm. open-label study will assess the efficacy and safety of Herceptin (trastuzumab) in combination with Xeloda (capecitabine) in patients with metastatic or recurrent HER2-positive breast cancer, refractory to or…
- Trial name
- NCT01290718
- Testing
- capecitabine [Xeloda], trastuzumab [Herceptin]
- Where
- 6 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
- Trial name
- NCT00556374
- Testing
- Denosumab, Non-steroidal aromatase inhibitor therapy, Zoledronic Acid
- Where
- 46 sites in Austria, Sweden
- Volunteers
- 3,420 people
- Sponsor
- Amgen
Breast Cancer
Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer
The purpose of this study is to determine whether UTD1 Injection in combination with capecitabine is effective in the treatment of advanced metastatic breast cancer using capecitabine as a control.
- Trial name
- NCT02253459
- Testing
- UTD1 Injection plus capecitabine, Capecitabine
- Where
- 11 sites in China
- Volunteers
- 405 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
This is a clinical trial with a crossover design to determine patients' preference for capecitabine in combination with bevacizumab or everolimus in combination with exemestane for advanced breast cancer patients and to evaluate…
- Conditions
- Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- IMPROVE (NCT02248571)
- Testing
- Bevacizumab, Capecitabine, Everolimus
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- iOMEDICO AG
Metastatic Breast Cancer
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.
- Trial name
- NCT01516307
- Testing
- OPT-822/OPT-821(30 μg/100 μg), Phosphate Buffer Saline (PBS), Cyclophosphamide
- Where
- 43 sites in United States, China and 3 more
- Volunteers
- 349 people
- Sponsor
- OBI Pharma, Inc
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in participants with PIK3CA-mutant, hormone…
- Trial name
- INAVO120 (NCT04191499)
- Testing
- Inavolisib, Palbociclib, Fulvestrant
- Where
- 135 sites in United States, Argentina and 26 more
- Volunteers
- 325 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Metastases
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
- Conditions
- Breast Cancer, Metastases, Bone Metastases in Subjects With Advanced Breast Cancer
- Trial name
- NCT00091832
- Testing
- Denosumab, IV Bisphosphonates
- Volunteers
- 255 people
- Sponsor
- Amgen
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts…
- Trial name
- NCT06686394
- Testing
- Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 181 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Non Small Cell Lung Carcinoma, Metastatic Breast Cancer
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule).
- Trial name
- NCT00890903
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Pierre Fabre Pharma GmbH
Breast Cancer, Triple Negative Breast Cancer
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
This is the first part of a 2-part study assessing the efficacy of AZD2281 in combination with paclitaxel in 1st or 2nd line treatment of patients with metastatic triple negative breast cancer.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT00707707
- Testing
- AZD2281, Paclitaxel
- Where
- 6 sites in Australia, Austria and 2 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Breast Neoplasm
Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®
This non-interventional study is designated as a Post Marketing Surveillance Study and is a commitment to Ministry of Food and Drug Safety (MFDS).
- Trial name
- NCT03445637
- Where
- South Korea
- Volunteers
- 552 people
- Sponsor
- Pfizer
Breast Cancer, HER2 Positive Breast Cancer
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus…
- Trial name
- HERMIONE (NCT02213744)
- Testing
- MM-302, Gemcitabine, Capecitabine
- Where
- 109 sites in United States, Austria and 7 more
- Volunteers
- 113 people
- Sponsor
- Merrimack Pharmaceuticals